Seeking Alpha: Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional ... Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional ... Novel mavacamten had a big impact on quality of life in obstructive hypertrophic cardiomyopathy, according to a secondary analysis of the EXPLORER-HCM trial.
The cardiac myosin inhibitor improved ... In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ... The Cardiology Advisor: ACC: Mavacamten Efficacious for Adolescents With Obstructive Hypertrophic Cardiomyopathy Medscape: Hypertrophic Obstructive Cardiomyopathy and Sleep-Disordered Breathing: An Under-Recognized and Unfavorable Association Despite extraordinary advances in understanding hypertrophic obstructive cardiomyopathy (HOCM) at the molecular and genetic level, the overall clinical management of patients with HOCM remains ... Asymmetrical septal hypertrophy that causes a left-ventricular outflow tract (LVOT) gradient is a common feature of hypertrophic obstructive cardiomyopathy (HCOM).
